Projekt

ETOP 10-16 BOOSTER: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with con-firmed EGFRm and T790M

Automatisch geschlossen · 2017 bis 2023

Früh Martin